Initiated Buy X

NVAX Novavax

BTIG Research

$19

Downgrades Neutral Underweight X

NVAX Novavax

JP Morgan

$8

Upgrades Underperform Neutral X

NVAX Novavax

BofA Securities

$4 $12

Upgrades Underweight Neutral X

NVAX Novavax

JP Morgan

Upgrades Neutral Buy X

NVAX Novavax

B. Riley Securities

$15

Downgrades Outperform Mkt Perform X

NVAX Novavax

TD Cowen

$55 $10

Downgrades Buy Neutral X

NVAX Novavax

B. Riley Securities

$29 $10

Reiterated Buy X

NVAX Novavax

B. Riley Securities

$74 $37

Reiterated Buy X

NVAX Novavax

H.C. Wainwright

$207 $110

Initiated Hold X

NVAX Novavax

Jefferies

Downgrades Neutral Underweight X

NVAX Novavax

JP Morgan

$132 $27

Initiated Underperform X

NVAX Novavax

BofA Securities

$35

Initiated Outperform X

NVAX Novavax

Cowen

$150

Downgrades Overweight Neutral X

NVAX Novavax

JP Morgan

$285 $161

Reiterated Buy X

NVAX Novavax

H.C. Wainwright

$10 $17

Downgrades Overweight Underweight X

NVAX Novavax

Piper Jaffray

$4.50 $0.25

Initiated Buy X

NVAX Novavax

Ladenburg Thalmann

$3

Initiated Outperform X

NVAX Novavax

Oppenheimer

$4

Upgrades Neutral Overweight X

NVAX Novavax

Piper Jaffray

Upgrades Underweight Overweight X

NVAX Novavax

JP Morgan

Upgrades Neutral Buy X

NVAX Novavax

Seaport Global Securities

$5

Downgrades Neutral Underweight X

NVAX Novavax

JP Morgan

Upgrades Neutral Buy X

NVAX Novavax

Citigroup

NVAX  Novavax, Inc.

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).